These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23343395)

  • 1. Issues in women's participation in a phase III community HIV vaccine trial in Thailand.
    Kaewkungwal J; Pitisuttithum P; Rerks-Ngarm S; Nitayaphan S; Khamboonruang C; Kunasol P; Suntharasamai P; Pungpak S; Vanijanonta S; Bussaratid V; Maek-A-Nantawat W; Dhitavat J; Thongcharoen P; Pawarana R; Sabmee Y; Benenson MW; Morgan P; O'Connell RJ; Kim J
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1524-34. PubMed ID: 23343395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.
    Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE
    AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148).
    Ministry of Public Health-Thai AIDS Vaccine Evaluation Group
    Vaccine; 2011 Jun; 29(25):4285-92. PubMed ID: 21435408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand.
    Jenkins RA; Chinaworapong S; Morgan PA; Ruangyuttikarn C; Sontirat A; Chiu J; Michael RA; Nitayaphan S; Khamboonruang C
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):171-7. PubMed ID: 9637582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
    Andersson KM; Stover J
    Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.
    Pitisuttithum P; Rerks-Ngarm S; Bussaratid V; Dhitavat J; Maekanantawat W; Pungpak S; Suntharasamai P; Vanijanonta S; Nitayapan S; Kaewkungwal J; Benenson M; Morgan P; O'Connell RJ; Berenberg J; Gurunathan S; Francis DP; Paris R; Chiu J; Stablein D; Michael NL; Excler JL; Robb ML; Kim JH
    PLoS One; 2011; 6(12):e27837. PubMed ID: 22205930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand.
    Markowitz LE; Sirisopana N; Charonwatanachokchai A; Julvanichpong W; Siraprapasiri T; Palanuvej T; Siriwongrangsun P; Tungsakul V; Pumratana K; Chitwarakorn A; Michael RA; Brown AE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(5):488-94. PubMed ID: 10225232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
    Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
    Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand.
    Jenkins RA; Thapinta D; Morgan PA; Wongkamhaeng S; Sornsathapornkul P; Bussaratid V; Sontirat A; Pitisuttithum P; Thongchareoen P; Khamboonruang C; Suriyanon V; Nitayaphan S; Brown AE;
    J Acquir Immune Defic Syndr; 2005 Dec; 40(5):592-9. PubMed ID: 16284537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
    Baden LR; Stieh DJ; Sarnecki M; Walsh SR; Tomaras GD; Kublin JG; McElrath MJ; Alter G; Ferrari G; Montefiori D; Mann P; Nijs S; Callewaert K; Goepfert P; Edupuganti S; Karita E; Langedijk JP; Wegmann F; Corey L; Pau MG; Barouch DH; Schuitemaker H; Tomaka F;
    Lancet HIV; 2020 Oct; 7(10):e688-e698. PubMed ID: 33010242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya.
    Jackson DJ; Martin HL; Bwayo JJ; Nyange PM; Rakwar JP; Kashonga F; Mandaliya K; Ndinya-Achola JO; Kreiss JK
    AIDS; 1995 Nov; 9(11):1279-83. PubMed ID: 8561982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
    Thongcharoen P; Suriyanon V; Paris RM; Khamboonruang C; de Souza MS; Ratto-Kim S; Karnasuta C; Polonis VR; Baglyos L; Habib RE; Gurunathan S; Barnett S; Brown AE; Birx DL; McNeil JG; Kim JH;
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):48-55. PubMed ID: 17909315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
    Robb ML; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Kunasol P; Khamboonruang C; Thongcharoen P; Morgan P; Benenson M; Paris RM; Chiu J; Adams E; Francis D; Gurunathan S; Tartaglia J; Gilbert P; Stablein D; Michael NL; Kim JH
    Lancet Infect Dis; 2012 Jul; 12(7):531-7. PubMed ID: 22652344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
    Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Kaewkungwal J; Chiu J; Paris R; Premsri N; Namwat C; de Souza M; Adams E; Benenson M; Gurunathan S; Tartaglia J; McNeil JG; Francis DP; Stablein D; Birx DL; Chunsuttiwat S; Khamboonruang C; Thongcharoen P; Robb ML; Michael NL; Kunasol P; Kim JH;
    N Engl J Med; 2009 Dec; 361(23):2209-20. PubMed ID: 19843557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand.
    Newman PA; Roungprakhon S; Tepjan S; Yim S
    Vaccine; 2010 Jan; 28(4):958-64. PubMed ID: 19925897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.
    Hemachandra A; Puls RL; Sirivichayakul S; Kerr S; Thantiworasit P; Ubolyam S; Cooper DA; Emery S; Phanuphak P; Kelleher A; Ruxrungtham K
    Hum Vaccin; 2010 Oct; 6(10):835-40. PubMed ID: 20864808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 prophylactic vaccine trials in Thailand.
    Pitisuttithum P
    Curr HIV Res; 2005 Jan; 3(1):17-30. PubMed ID: 15638720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.
    Nitayaphan S; Pitisuttithum P; Karnasuta C; Eamsila C; de Souza M; Morgan P; Polonis V; Benenson M; VanCott T; Ratto-Kim S; Kim J; Thapinta D; Garner R; Bussaratid V; Singharaj P; el-Habib R; Gurunathan S; Heyward W; Birx D; McNeil J; Brown AE;
    J Infect Dis; 2004 Aug; 190(4):702-6. PubMed ID: 15272397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.